Verve’s Cholesterol Gene Editing Hits Milestone – With Lilly Now Onboard
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.
You may also be interested in...
Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.
Lilly expects the obesity drug will be fully accessible in a therapeutic area that has experienced short supply. The list price will be 20% lower than the price of Wegovy.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.